Company / Cash & Equivalents
LEXICON PHARMACEUTICALS, INC. Cash & Equivalents History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$34.3M
FY2025
5-year range
$22.5M / $66.7M
FY2021-FY2025
Trend
-48.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $22M in FY2023 to $203M in FY2017.
Based on SEC 10-K filings.
$34M in FY2025 with a 10-year CAGR of -0.9%.
Improved from $22M to $34M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -0.9%
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 48.5% year-over-year.
- Peak cash & equivalents was recorded in FY2017.
- Lowest cash & equivalents in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.3M | -48.5% |
| FY2024 | $66.7M | +196.7% |
| FY2023 | $22.5M | -64.9% |
| FY2019 | $64.1M | +37.5% |
| FY2018 | $46.6M | -77.0% |
| FY2017 | $203.0M | +47.9% |
| FY2016 | $137.3M | +266.1% |
| FY2015 | $37.5M | +23.3% |
| FY2014 | $30.4M | -83.7% |
| FY2013 | $186.3M | +294.7% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026